Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round

pharmanewsdaily- June 17, 2020 0

California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 ... Read More

4D Molecular Therapeutics’ 4D-110 receives FDA orphan drug designation for choroideremia

pharmanewsdaily- November 17, 2018 0

4D Molecular Therapeutics (4DMT), a prominent California-based gene therapy firm, has achieved a significant milestone with the US Food and Drug Administration (FDA) granting orphan ... Read More

4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations

pharmanewsdaily- September 6, 2018 0

California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More